Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” ” . . In addition, Gb Sciences has 12 U.S.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

NOVEMBER 19, 2021

19, 2021 /CNW/ – PsyBio Therapeutics Corp. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

NOVEMBER 26, 2021

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. On September 30, 2021, Can-Fite had approximately $13.3 Fortified Balance Sheet.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

SEPTEMBER 22, 2021

Pnina Fishman will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021 and will join a panel discussion regarding medical cannabis. Date: Wednesday, September 29, 2021. Date: Wednesday, September 29, 2021. Details are below: Medical Cannabis Panel. Time: 11:55 am – 12:35 pm ET. To view live: link.

Clinical Trials 52

Clinical Trials Treatment Business Events 52

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Actual results and future events could differ materially from those anticipated in such information.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JULY 29, 2021

VANCOUVER, BC , July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products. On Behalf of the Board.

Clinical Trials 105

Clinical Trials Conditions Packaging Events 105

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. million as of September 30, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

NOVEMBER 1, 2021

The findings have been published in an abstract in the October 2021 supplement of HEPATOLOGY , a premier peer-reviewed publication in the field of liver disease published on behalf of the AASLD. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. Our next series of MDT webinars on cannabis for symptom management in oncology takes place on March 29, 2021.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. About Oravax Medical.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

OCTOBER 15, 2021

PAOG’s RespRx research has shown effectiveness in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. RespRx, in addition to its clinical research with COPD, has been engaged in select, non-clinical trials to treat cancer and demonstrated effectiveness. USOTC: USMJ).

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — SciSparc Ltd. OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 15, 2021

Xebra’s 125,619,492 issued and outstanding common shares will commence trading at market open on Monday, October 18, 2021 under the ticker symbol “ XBRA “. Planting of the first trial crop is expected to commence in December 2021 , which will be harvested and submitted to the Dutch government in March 2022. THE NETHERLANDS.

Seed-To-Sale 52

Seed-To-Sale Cultivation Clinical Trials Cannabinoids 52

Cannabis Law Report

NOVEMBER 12, 2021

Released 07:00:14 01 November 2021. 01 November 2021. 1 November 2021. of the voting rights of KCP in the Company) that on 1 July 2021, KCP was offered a facility of £1,000,000 by Brown Shipley & Co Limited (“Brown Shipley”) by way of an overdraft (the “Facility”). RNS Number : 8293Q.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

AUGUST 24, 2021

A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed by MyMD on August 16, 2021. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JUNE 7, 2021

Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S. Food and Drug Administration (U.S.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. Brett Maas.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

AUGUST 26, 2022

Apart from this, various clinical trials are done for multiple conditions. billion in 2021. Seizures and epilepsy are serious medical conditions. Across the globe, up to 65 million people suffer from these conditions. The triggers are events that happen before the seizure starts. Conclusion.

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

JUNE 7, 2021

A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. 646-536-7331.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

OCTOBER 5, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. The Company’s presentation will be available for viewing that day at 10:10 a.m.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. royalty on all future net sales.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

OCTOBER 19, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. MyMD Chief Scientific Officer Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 15, 2021

2021 Aug 26;23:119-127. eCollection 2021 Dec 10. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. doi: 10.1016/j.omtm.2021.08.006.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

JULY 7, 2021

A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed by MyMD on May 18, 2021. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105